Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: Final analysis from the PROPHESYS cohort
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1111/jvh.12179 http://hdl.handle.net/11449/220127 |
Resumo: | The population of patients with chronic hepatitis C viral infection is ageing; however, elderly, hepatitis C-infected patients are understudied and less frequently treated. This subanalysis of data from the multinational PROPHESYS study examined associations between age (≤65 vs >65 years), on-treatment virological response and sustained virological response (SVR) in patients treated with peginterferon alfa-2a (40KD)/ribavirin in accordance with local licences. PROPHESYS comprised three cohorts studied in 19 countries according to country-specific legal and regulatory requirements. This subanalysis includes treatment-naive HCV mono-infected patients assigned to receive peginterferon alfa-2a (40KD)/ribavirin, with 6276 individuals aged ≤65 years and 349 aged >65 years. Rapid virological response (RVR) rates by Week 4 were consistently lower in older genotype (G) 1 (21.6% vs 27.2% in younger patients), G2 (80.7% vs 85.1%) and G3 (60.0% vs 74.2%) patients. SVR rates were significantly lower (29.8% vs 43.0%) and relapse rates significantly higher (43.1% vs 26.7%) in older G1 patients (P = 0.0002 vs ≤65 years). In contrast, SVR and relapse rates were similar in G2 and G3 patients regardless of age. The positive predictive value of RVR for SVR was comparable in older and younger G1 patients (66.7% vs 68.6%, respectively) and higher in older G2 (80.7% vs 75.6%) and G3 (77.8% vs 66.8%) patients. Virological response rates are generally lower in elderly CHC patients, and RVR is a reliable positive predictor of SVR in patients >65 years. © 2013 John Wiley & Sons Ltd. |
id |
UNSP_ef0b789bf039b07cb1485450827f180c |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/220127 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: Final analysis from the PROPHESYS cohortelderly patientshepatitis C viruspeginterferon alfa-2a/ribavirinsustained virological responsetreatment-naiveviral kineticsThe population of patients with chronic hepatitis C viral infection is ageing; however, elderly, hepatitis C-infected patients are understudied and less frequently treated. This subanalysis of data from the multinational PROPHESYS study examined associations between age (≤65 vs >65 years), on-treatment virological response and sustained virological response (SVR) in patients treated with peginterferon alfa-2a (40KD)/ribavirin in accordance with local licences. PROPHESYS comprised three cohorts studied in 19 countries according to country-specific legal and regulatory requirements. This subanalysis includes treatment-naive HCV mono-infected patients assigned to receive peginterferon alfa-2a (40KD)/ribavirin, with 6276 individuals aged ≤65 years and 349 aged >65 years. Rapid virological response (RVR) rates by Week 4 were consistently lower in older genotype (G) 1 (21.6% vs 27.2% in younger patients), G2 (80.7% vs 85.1%) and G3 (60.0% vs 74.2%) patients. SVR rates were significantly lower (29.8% vs 43.0%) and relapse rates significantly higher (43.1% vs 26.7%) in older G1 patients (P = 0.0002 vs ≤65 years). In contrast, SVR and relapse rates were similar in G2 and G3 patients regardless of age. The positive predictive value of RVR for SVR was comparable in older and younger G1 patients (66.7% vs 68.6%, respectively) and higher in older G2 (80.7% vs 75.6%) and G3 (77.8% vs 66.8%) patients. Virological response rates are generally lower in elderly CHC patients, and RVR is a reliable positive predictor of SVR in patients >65 years. © 2013 John Wiley & Sons Ltd.University of Chicago Medical Center, 5841 S. Maryland Avenue, Chicago, IL 60637Clinical Hospital Dr. I. Cantacuzino, BucharestMatei Bals Infectious Diseases Institute, BucharestUnità Operativa Epatologia Ed Ecografia Interventistica Ospedale Gragnano, NaplesClinic for Infectious Disease, Clinical Center Serbia, BelgradeDivisione di Medicina Interna, Ospedale Regina Margherita, ComisoRoyal Free and University College School of Medicine, London2nd Department of Medicine, Semmelweis University, BudapestHôpital Beaujon, ClichyAzienda Ospedaliero-Universitaria di Parma, ParmaHigh Desert Gastroenterology Suite B, Lancaster, CABotucatu School of Medicine, BotucatuDivisione di Medicina, Ospedale Elena d'Aosta, NapoliIST GmbH, MannheimF. Hoffmann-La Roche, BaselGenentech, South San Francisco, CAHospital de Clinicas de Porto Alegre, Porto AlegreUniversity of Chicago Medical CenterClinical Hospital Dr. I. CantacuzinoMatei Bals Infectious Diseases InstituteUnità Operativa Epatologia Ed Ecografia Interventistica Ospedale GragnanoClinic for Infectious Disease, Clinical Center SerbiaDivisione di Medicina Interna, Ospedale Regina MargheritaRoyal Free and University College School of Medicine2nd Department of Medicine, Semmelweis UniversityHôpital BeaujonAzienda Ospedaliero-Universitaria di ParmaHigh Desert Gastroenterology Suite BBotucatu School of MedicineDivisione di Medicina, Ospedale Elena d'AostaIST GmbHF. Hoffmann-La RocheGenentechHospital de Clinicas de Porto AlegreAronsohn, A.Ancuta, I.Caruntu, F.Coppola, C.Delic, D.Digiacomo, A.Dusheiko, G. M.Lengyel, G.Marcellin, P.Orlandini, A.Pruthi, J.Silva, G. F.Tallarico, L.Schmitz, M.Tatsch, F.Korner, E.Cheinquer, H.2022-04-28T18:59:47Z2022-04-28T18:59:47Z2014-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article377-380http://dx.doi.org/10.1111/jvh.12179Journal of Viral Hepatitis, v. 21, n. 5, p. 377-380, 2014.1365-28931352-0504http://hdl.handle.net/11449/22012710.1111/jvh.121792-s2.0-84898426682Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengJournal of Viral Hepatitisinfo:eu-repo/semantics/openAccess2022-04-28T18:59:48Zoai:repositorio.unesp.br:11449/220127Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T15:11:42.419241Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: Final analysis from the PROPHESYS cohort |
title |
Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: Final analysis from the PROPHESYS cohort |
spellingShingle |
Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: Final analysis from the PROPHESYS cohort Aronsohn, A. elderly patients hepatitis C virus peginterferon alfa-2a/ribavirin sustained virological response treatment-naive viral kinetics |
title_short |
Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: Final analysis from the PROPHESYS cohort |
title_full |
Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: Final analysis from the PROPHESYS cohort |
title_fullStr |
Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: Final analysis from the PROPHESYS cohort |
title_full_unstemmed |
Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: Final analysis from the PROPHESYS cohort |
title_sort |
Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: Final analysis from the PROPHESYS cohort |
author |
Aronsohn, A. |
author_facet |
Aronsohn, A. Ancuta, I. Caruntu, F. Coppola, C. Delic, D. Digiacomo, A. Dusheiko, G. M. Lengyel, G. Marcellin, P. Orlandini, A. Pruthi, J. Silva, G. F. Tallarico, L. Schmitz, M. Tatsch, F. Korner, E. Cheinquer, H. |
author_role |
author |
author2 |
Ancuta, I. Caruntu, F. Coppola, C. Delic, D. Digiacomo, A. Dusheiko, G. M. Lengyel, G. Marcellin, P. Orlandini, A. Pruthi, J. Silva, G. F. Tallarico, L. Schmitz, M. Tatsch, F. Korner, E. Cheinquer, H. |
author2_role |
author author author author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
University of Chicago Medical Center Clinical Hospital Dr. I. Cantacuzino Matei Bals Infectious Diseases Institute Unità Operativa Epatologia Ed Ecografia Interventistica Ospedale Gragnano Clinic for Infectious Disease, Clinical Center Serbia Divisione di Medicina Interna, Ospedale Regina Margherita Royal Free and University College School of Medicine 2nd Department of Medicine, Semmelweis University Hôpital Beaujon Azienda Ospedaliero-Universitaria di Parma High Desert Gastroenterology Suite B Botucatu School of Medicine Divisione di Medicina, Ospedale Elena d'Aosta IST GmbH F. Hoffmann-La Roche Genentech Hospital de Clinicas de Porto Alegre |
dc.contributor.author.fl_str_mv |
Aronsohn, A. Ancuta, I. Caruntu, F. Coppola, C. Delic, D. Digiacomo, A. Dusheiko, G. M. Lengyel, G. Marcellin, P. Orlandini, A. Pruthi, J. Silva, G. F. Tallarico, L. Schmitz, M. Tatsch, F. Korner, E. Cheinquer, H. |
dc.subject.por.fl_str_mv |
elderly patients hepatitis C virus peginterferon alfa-2a/ribavirin sustained virological response treatment-naive viral kinetics |
topic |
elderly patients hepatitis C virus peginterferon alfa-2a/ribavirin sustained virological response treatment-naive viral kinetics |
description |
The population of patients with chronic hepatitis C viral infection is ageing; however, elderly, hepatitis C-infected patients are understudied and less frequently treated. This subanalysis of data from the multinational PROPHESYS study examined associations between age (≤65 vs >65 years), on-treatment virological response and sustained virological response (SVR) in patients treated with peginterferon alfa-2a (40KD)/ribavirin in accordance with local licences. PROPHESYS comprised three cohorts studied in 19 countries according to country-specific legal and regulatory requirements. This subanalysis includes treatment-naive HCV mono-infected patients assigned to receive peginterferon alfa-2a (40KD)/ribavirin, with 6276 individuals aged ≤65 years and 349 aged >65 years. Rapid virological response (RVR) rates by Week 4 were consistently lower in older genotype (G) 1 (21.6% vs 27.2% in younger patients), G2 (80.7% vs 85.1%) and G3 (60.0% vs 74.2%) patients. SVR rates were significantly lower (29.8% vs 43.0%) and relapse rates significantly higher (43.1% vs 26.7%) in older G1 patients (P = 0.0002 vs ≤65 years). In contrast, SVR and relapse rates were similar in G2 and G3 patients regardless of age. The positive predictive value of RVR for SVR was comparable in older and younger G1 patients (66.7% vs 68.6%, respectively) and higher in older G2 (80.7% vs 75.6%) and G3 (77.8% vs 66.8%) patients. Virological response rates are generally lower in elderly CHC patients, and RVR is a reliable positive predictor of SVR in patients >65 years. © 2013 John Wiley & Sons Ltd. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-01-01 2022-04-28T18:59:47Z 2022-04-28T18:59:47Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1111/jvh.12179 Journal of Viral Hepatitis, v. 21, n. 5, p. 377-380, 2014. 1365-2893 1352-0504 http://hdl.handle.net/11449/220127 10.1111/jvh.12179 2-s2.0-84898426682 |
url |
http://dx.doi.org/10.1111/jvh.12179 http://hdl.handle.net/11449/220127 |
identifier_str_mv |
Journal of Viral Hepatitis, v. 21, n. 5, p. 377-380, 2014. 1365-2893 1352-0504 10.1111/jvh.12179 2-s2.0-84898426682 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Journal of Viral Hepatitis |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
377-380 |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808128477912629248 |